Several reports have shown that the functional outcome of CD16-dependent tumor-targeting mAb activation may be negatively affected by the simultaneous engagement of MHC-I inhibitory receptors in vitro [147,177,178,179,180,181]. The gene discussed is FCGR3A; the disease is neoplasm.